Clinical trials: Melanoma Stage
Metastatic Melanoma
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
This open-label phase II trial studies how well niraparib works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
- Trial name
- NCT03925350
- Testing
- Niraparib
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- California Pacific Medical Center Research Institute
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma
- Trial name
- NCT04544748
- Testing
- GNR-051
- Where
- 12 sites in Russia
- Volunteers
- 48 people
- Sponsor
- AO GENERIUM
Melanoma (Skin)
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00755976
- Testing
- epirubicin hydrochloride, sulindac, immunologic technique
- Where
- 10 sites in Ireland
- Volunteers
- 32 people
- Sponsor
- Cancer Trials Ireland
Melanoma, Cancer
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.
- Trial name
- PREMIUM (NCT05097378)
- Testing
- Encorafenib + Binimetinib, Standard Adjuvant Treatment
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- CCTU- Cancer Theme
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Melanoma
Imatinib in Adult Patients With Metastatic Ocular Melanoma
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
- Trial name
- O-Mel-Inib (NCT00421317)
- Testing
- Imatinib
- Where
- 12 sites in France
- Volunteers
- 13 people
- Sponsor
- Centre Oscar Lambret
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma Stage Iv, Melanoma Stage Iii
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma.
- Conditions
- Melanoma Stage Iv, Melanoma Stage Iii, Melanoma
- Trial name
- CHARLI (NCT03161756)
- Testing
- Denosumab, Nivolumab, Ipilimumab
- Where
- 10 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year.
- Trial name
- NCT04844528
- Testing
- Nicotinamide
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of Utah
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.
- Trial name
- NCT05572463
- Testing
- Sintilimab + IBI110
- Where
- 13 sites in United States, Australia and 5 more
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Melanoma
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
This is an international multicenter, open-label, sequential phase study of intralesional (IL) PV-10 in combination with immune checkpoint inhibition.
- Trial name
- NCT02557321
- Testing
- PV-10, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Melanoma (Skin)
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00054535
- Testing
- aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Cutaneous Melanoma
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma.
- Trial name
- NCT00679289
- Testing
- HDI, KW2871
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma, Neoplasm
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
- Trial name
- NCT00062491
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Malignant Melanoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
The purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line…
- Trial name
- NCT04889118
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 11 sites in China
- Volunteers
- 131 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
- Trial name
- NCT01864538
- Testing
- TH-302
- Where
- 7 sites in United States, Canada
- Volunteers
- 11 people
- Sponsor
- ImmunoGenesis
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG